Professional
Added to YB: 2026-04-13
Pitch date: 2026-04-10
NKTR [neutral]
Nektar Therapeutics
-51.03%
current return
Author Info
No bio for this author
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$77.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.43
P/E
-6.53
EV/Sales
16.36
Sector
Biotechnology
Category
growth
Cedar Grove Capital Management Portfolio Holding: Nektar Therapeutics
NKTR (holding update): Biotech w/ rezpegaldesleukin targeting atopic dermatitis (80M patients globally, >$50B market) & alopecia areata. Competitive efficacy vs JAK inhibitors but cleaner safety profile, strong durability, quarterly dosing = best-in-class potential post-biologics. Peak sales $3-$5B vs ~$2B EV. Catalyst: P3 data. Prefer buyout over commercialization.
Read full article (1 min)